Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer

Surgery

Volumn 129, Issue 2, 2001, Pages 176-187

  Bartlett, David L ^a   Libutti, Steven K ^a   Figg, William D ^a   Fraker, Douglas L ^a   Richard Alexander, H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FOLINIC ACID; MELPHALAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATIC ARTERY; HUMAN; HYPERTHERMIA; ISOLATED LIVER; LIVER METASTASIS; LIVER PERFUSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

EID: 0035137038     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2001.110365     Document Type: Article

References (44)

1. Cancer Statistics, 1999
2. Metastatic cancer to the liver
3. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma
4. No treatment option for liver metastases from colorectal adenocarcinoma
5. Prognosis of untreated liver metastasis from rectal cancer
6. Surgical options in the treatment of hepatic metastasis from colorectal cancer
7. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer
8. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum
9. Management of hepatic metastases
10. Surgical treatment and other regional treatments for colorectal cancer liver metastases
11. Hepatic arterial chemotherapy in metastatic colorectal patients
12. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California oncology group trial
13. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma
14. A prospective randomized trial of regional versus systemic continuous fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases
15. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer
16. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: Is there a survival difference? Meta-analysis of the published literature
17. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer
18. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma
19. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases
20. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver
21. Development of a technic for isolated perfusion of the liver
22. Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver
23. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
24. Isolated perfusion of the liver
25. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs
26. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients
27. The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma
28. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan
29. Die isolierte leberperfusion mit 5-fluorouracil (5-FU) beim menschen
30. Rationale and indications for perfusion in liver tumors: Current data
31. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver
32. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy
33. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia tumour necrosis factor alpha and melphalan
34. Isolated hepatic perfusion with tumor necrosis factor alpha and melaphalan: Experimental studies in pigs and phase I data from humans
35. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis
36. Clinical results of hyperthermic liver perfusion for cancer in the liver
37. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma
38. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases
39. Tumor necrosis factor: Basic principles and clinical application in systemic and regional cancer treatment
40. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1
41. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins
42. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor independent mechanisms
43. Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma
44. Update on hepatic intra-arterial chemotherapy